Aysegul Yildiz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Aysegul Yildiz has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Donna Pauler Ankerst
Technical University of Munich
4 shared publications - Eduard Vieta
University of Barcelona: Universitat de Barcelona
4 shared publications Gary S. Sachs
Harvard Medical School, Massachusetts General Hospital, Bipolar Program, Boston, MA, USA
4 shared publicationsPerry F. Renshaw
4 shared publicationsGary S Sachs
2 shared publications- Necati Gökmen
Dokuz Eylul University
2 shared publications
Latest Publications
- 1 June 2015
- Published by Oxford University Press (OUP)
- p. 599-622
Strategies for Improving Randomized Trial Evidence for Treatment of Bipolar Disorder
Treatment of bipolar disorder involves acute and maintenance phases with special considerations for manic and depressive episodes. As such, accumulated randomized controlled trials (RCTs) based evidence for treatment options of acute bipolar depression, mania, or maintenance phases require independent considerations. This chapter reviews methodological obstacles that are impeding progress in the development of therapeutic strategies for treatment of this serious illness and recommends strategies aimed at aiding improvement of future trials. Challenges encountered in design and conduct of the RCTs of bipolar depression, mania, and prophylaxis are considered independently. In each of these trial sets, limitations of existing evidence and strategies for their improvement are discussed.
- 1 June 2015
- Published by Oxford University Press (OUP)
- p. 599-622
Strategies for Improving Randomized Trial Evidence for Treatment of Bipolar Disorder
Treatment of bipolar disorder involves acute and maintenance phases with special considerations for manic and depressive episodes. As such, accumulated randomized controlled trials (RCTs) based evidence for treatment options of acute bipolar depression, mania, or maintenance phases require independent considerations. This chapter reviews methodological obstacles that are impeding progress in the development of therapeutic strategies for treatment of this serious illness and recommends strategies aimed at aiding improvement of future trials. Challenges encountered in design and conduct of the RCTs of bipolar depression, mania, and prophylaxis are considered independently. In each of these trial sets, limitations of existing evidence and strategies for their improvement are discussed.
- 1 November 2014
- Published by Wolters Kluwer Health in Harvard Review of Psychiatry
- Vol. 22 (6) , 325
Introduction
- 1 November 2014
- Published by Wolters Kluwer Health in Harvard Review of Psychiatry
- Vol. 22 (6) , 325
Introduction
- 18 July 2014
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 45 (2) , 299-317
A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania
Background: Evidence synthesis methods enabling direct and indirect comparisons over the entire set of relevant clinical data produce quantitative point estimates for the treatments contrasts between competing interventions, and provide a hierarchical rank ordering between them. We aimed to provide evidence-based guidance on the efficacy and all-cause discontinuation of antimanic treatments.Method: We conducted a network meta-analysis within a Bayesian framework. We searched all standard literature databases without language restrictions up to 15 January 2014 to identify reports of short-term, randomized, blinded trials of putative antimanic drugs as monotherapy for adults with bipolar-I mania.Results: Altogether, 14256 manic patients randomized to one of 18 active treatments or placebo provided 95 direct comparisons on 128 data points. For the primary outcome, standardized mean difference as Hedges’ g (standardized mean difference; SMD), the hierarchies indicated by surface under the cumulative ranking (SUCRA) probabilities were in agreement with the point estimates for all antimanic drugs identified as effective. For the 12 effective antimanic drugs on clinical use, SMDs against placebo ranged from 0.32 to 0.66 without superiority of one over another, except for risperidone v. aripiprazole and valproate. Aripiprazole, olanzapine, quetiapine, risperidone, and valproate had less all-cause discontinuation rates than placebo. Sensitivity analysis by drug class indicated similar efficacy profiles for haloperidol, second-generation antipsychotics, and mood stabilizers.Conclusions: Hierarchical rank ordering by comparative efficacy and risk of all-cause discontinuations should help to guide antimanic treatment choices by clinicians, healthcare policy makers, and guideline developers.
- 18 July 2014
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 45 (2) , 299-317
A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania
Background: Evidence synthesis methods enabling direct and indirect comparisons over the entire set of relevant clinical data produce quantitative point estimates for the treatments contrasts between competing interventions, and provide a hierarchical rank ordering between them. We aimed to provide evidence-based guidance on the efficacy and all-cause discontinuation of antimanic treatments.Method: We conducted a network meta-analysis within a Bayesian framework. We searched all standard literature databases without language restrictions up to 15 January 2014 to identify reports of short-term, randomized, blinded trials of putative antimanic drugs as monotherapy for adults with bipolar-I mania.Results: Altogether, 14256 manic patients randomized to one of 18 active treatments or placebo provided 95 direct comparisons on 128 data points. For the primary outcome, standardized mean difference as Hedges’ g (standardized mean difference; SMD), the hierarchies indicated by surface under the cumulative ranking (SUCRA) probabilities were in agreement with the point estimates for all antimanic drugs identified as effective. For the 12 effective antimanic drugs on clinical use, SMDs against placebo ranged from 0.32 to 0.66 without superiority of one over another, except for risperidone v. aripiprazole and valproate. Aripiprazole, olanzapine, quetiapine, risperidone, and valproate had less all-cause discontinuation rates than placebo. Sensitivity analysis by drug class indicated similar efficacy profiles for haloperidol, second-generation antipsychotics, and mood stabilizers.Conclusions: Hierarchical rank ordering by comparative efficacy and risk of all-cause discontinuations should help to guide antimanic treatment choices by clinicians, healthcare policy makers, and guideline developers.
- Open Access
- 6 December 2012
- Published by Springer Nature
SMRI-02T-162A: double blind placebo controlled trial of a protein kinase C inhibitor: tamoxifen citrate in treatment of acute mania
- 6 December 2012
- Published by Springer Nature
Open AccessSMRI-02T-162A: double blind placebo controlled trial of a protein kinase C inhibitor: tamoxifen citrate in treatment of acute mania
- Open Access
- 7 February 2011
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 14 (07) , 863-875
Factors modifying drug and placebo responses in randomized trials for bipolar mania
Randomized placebo-controlled trials (RCTs) are standard for assessing efficacy and safety of treatments. We pursued preliminary indications that som
- 7 February 2011
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 14 (07) , 863-875
Open AccessFactors modifying drug and placebo responses in randomized trials for bipolar mania
Randomized placebo-controlled trials (RCTs) are standard for assessing efficacy and safety of treatments. We pursued preliminary indications that som
- 1 December 2010
- Published by Elsevier in Psychiatry Research: Neuroimaging
- Vol. 184 (3) , 162-170
In vivo proton magnetic resonance spectroscopic examination of benzodiazepine action in humans
- 1 December 2010
- Published by Elsevier in Psychiatry Research: Neuroimaging
- Vol. 184 (3) , 162-170
In vivo proton magnetic resonance spectroscopic examination of benzodiazepine action in humans
- 27 October 2010
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 36 (2) , 375-389
Efficacy of Antimanic Treatments: Meta-analysis of Randomized, Controlled Trials
We conducted meta-analyses of findings from randomized, placebo-controlled, short-term trials for acute mania in manic or mixed states of DSM (III–IV) bipolar I disorder in 56 drug–placebo comparisons of 17 agents from 38 studies involving 10 800 patients. Of drugs tested, 13 (76%) were more effective than placebo: aripiprazole, asenapine, carbamazepine, cariprazine, haloperidol, lithium, olanzapine, paliperdone, quetiapine, risperidone, tamoxifen, valproate, and ziprasidone. Their pooled effect size for mania improvement (Hedges’ g in 48 trials) was 0.42 (confidence interval (CI): 0.36–0.48); pooled responder risk ratio (46 trials) was 1.52 (CI: 1.42–1.62); responder rate difference (RD) was 17% (drug: 48%, placebo: 31%), yielding an estimated number-needed-to-treat of 6 (all p’ g=0.26–0.46); limited data indicated large effect sizes (Hedges’ g=0.51–2.32) for: carbamazepine, cariprazine, haloperidol, risperidone, and tamoxifen. The findings support the efficacy of most clinically used antimanic treatments, but encourage more head-to-head studies and development of agents with even greater efficacy.
- 27 October 2010
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 36 (2) , 375-389
Efficacy of Antimanic Treatments: Meta-analysis of Randomized, Controlled Trials
We conducted meta-analyses of findings from randomized, placebo-controlled, short-term trials for acute mania in manic or mixed states of DSM (III–IV) bipolar I disorder in 56 drug–placebo comparisons of 17 agents from 38 studies involving 10 800 patients. Of drugs tested, 13 (76%) were more effective than placebo: aripiprazole, asenapine, carbamazepine, cariprazine, haloperidol, lithium, olanzapine, paliperdone, quetiapine, risperidone, tamoxifen, valproate, and ziprasidone. Their pooled effect size for mania improvement (Hedges’ g in 48 trials) was 0.42 (confidence interval (CI): 0.36–0.48); pooled responder risk ratio (46 trials) was 1.52 (CI: 1.42–1.62); responder rate difference (RD) was 17% (drug: 48%, placebo: 31%), yielding an estimated number-needed-to-treat of 6 (all p’ g=0.26–0.46); limited data indicated large effect sizes (Hedges’ g=0.51–2.32) for: carbamazepine, cariprazine, haloperidol, risperidone, and tamoxifen. The findings support the efficacy of most clinically used antimanic treatments, but encourage more head-to-head studies and development of agents with even greater efficacy.
- 1 June 2010
- Published by Wolters Kluwer Health in The Journal of ECT
- Vol. 26 (2) , 104-110
Combination of Pharmacotherapy With Electroconvulsive Therapy in Prevention of Depressive Relapse
Relapse rates after electroconvulsive therapy (ECT) remain high with standard treatments. We aimed to test the efficacy of an early administered continuation pharmacotherapy (c-pharm early) strategy in prevention of post-ECT relapse. A 20-week, randomized, double-blind, placebo-controlled trial. Patients aged 18 to 65 years diagnosed with Diagnostic and Statistical Manual of Mental Disorders major depressive disorder, with or without psychotic features, with initial Montgomery-Asberg Depression Rating Scale scores higher than 22, underwent 8 bilateral ECT sessions (2 per week). Randomization to c-pharm early, c-pharm late, and placebo groups in 2:2:1, respectively, was performed at the completion of the fourth ECT session. After randomization, subjects in the c-pharm early group were given sertraline at 150 mg/d. Subjects in the c-pharm late group were first given placebo, which was substituted with sertraline at 150 mg/d at the completion of the eight ECT. Relapse was defined as a Montgomery-Asberg Depression Rating Scale score of 16 or higher. Seventy-three percent of the patients responded to the given treatment. The relapse rates were 12.5% in the c-pharm early group, 28% in the c-pharm late group, and 67% in the placebo group (P = 0.09). The c-pharm early strategy resulted in significantly lower relapse rates and longer well time compared with the placebo (P = 0.04). When the trend with the initiation of the c-pharm intervention was investigated in the 3 groups with equally spaced trend weights, the time of initiation was found to have a significant effect on the probability of the remaining well (P = 0.03). Comparative efficacy of c-pharm early and late strategies in providing improved protection against post-ECT relapse of major depressive disorder needs to be further explored.
- 1 June 2010
- Published by Wolters Kluwer Health in The Journal of ECT
- Vol. 26 (2) , 104-110
Combination of Pharmacotherapy With Electroconvulsive Therapy in Prevention of Depressive Relapse
Relapse rates after electroconvulsive therapy (ECT) remain high with standard treatments. We aimed to test the efficacy of an early administered continuation pharmacotherapy (c-pharm early) strategy in prevention of post-ECT relapse. A 20-week, randomized, double-blind, placebo-controlled trial. Patients aged 18 to 65 years diagnosed with Diagnostic and Statistical Manual of Mental Disorders major depressive disorder, with or without psychotic features, with initial Montgomery-Asberg Depression Rating Scale scores higher than 22, underwent 8 bilateral ECT sessions (2 per week). Randomization to c-pharm early, c-pharm late, and placebo groups in 2:2:1, respectively, was performed at the completion of the fourth ECT session. After randomization, subjects in the c-pharm early group were given sertraline at 150 mg/d. Subjects in the c-pharm late group were first given placebo, which was substituted with sertraline at 150 mg/d at the completion of the eight ECT. Relapse was defined as a Montgomery-Asberg Depression Rating Scale score of 16 or higher. Seventy-three percent of the patients responded to the given treatment. The relapse rates were 12.5% in the c-pharm early group, 28% in the c-pharm late group, and 67% in the placebo group (P = 0.09). The c-pharm early strategy resulted in significantly lower relapse rates and longer well time compared with the placebo (P = 0.04). When the trend with the initiation of the c-pharm intervention was investigated in the 3 groups with equally spaced trend weights, the time of initiation was found to have a significant effect on the probability of the remaining well (P = 0.03). Comparative efficacy of c-pharm early and late strategies in providing improved protection against post-ECT relapse of major depressive disorder needs to be further explored.
- 1 March 2008
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 65 (3) , 255-263
Protein Kinase C Inhibition in the Treatment of Mania
Research from JAMA Psychiatry — Protein Kinase C Inhibition in the Treatment of Mania — A Double-blind, Placebo-Controlled Trial of Tamoxifen
- 1 March 2008
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 65 (3) , 255-263
Protein Kinase C Inhibition in the Treatment of Mania
Research from JAMA Psychiatry — Protein Kinase C Inhibition in the Treatment of Mania — A Double-blind, Placebo-Controlled Trial of Tamoxifen
- 7 September 2006
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 31 (2) , 591
Corrigendum to “Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: A systematic review of the in vivo proton magnetic resonance spectroscopy findings” [Progress in Neuro-Psychopharmacology & Biological Psychiatry 30 (2006) 969–995]
- 7 September 2006
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 31 (2) , 591
Corrigendum to “Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: A systematic review of the in vivo proton magnetic resonance spectroscopy findings” [Progress in Neuro-Psychopharmacology & Biological Psychiatry 30 (2006) 969–995]